Ophthalmology-Focused Angel Investing
Early Capital.
Expert Insight.
Singular Focus.
An ophthalmology-focused investment community where deep domain expertise, rigorous diligence, and a genuine passion for early-stage innovation come together.
100+
Clinical trials conducted by our principals across opthalmology
30+
Years average clinical experience among EyeSci principals
9
Ophthalmic verticals actively evaluated — from therapeutics to AI
2
Membership tiers — start free, invest when you're ready
WHO WE ARE
Built for investors who want meaningful exposure to ophthalmology innovation.
We built EyeSci Angels for investors who want meaningful exposure to early-stage ophthalmology but may not have access to deal flow, diligence infrastructure, or perspective that comes from investing alongside domain experts who have spent careers at the intersection of clinical practice, early-stage investing, and company building.
THERAPEUTICS / DEVICES / DIAGNOSTICS / DRUG DELIVERY / SURGICAL TECHNOLOGIES / REGENERATIVE MEDICINE / IMAGING / AI / ENABLING PLATFORMS
Clinical Expertise
Domain experts at the intersection of clinical practice and early-stage investing.
Diligence Infrastructure
Structured evaluation across clinical, regulatory, reimbursement, and commercial dimensions.
Co-Investment Model
Principals and advisors invest alongside members in every deal.
Deal Flow Access
Curated early-stage opportunities sourced from a deep professional network.
WHY SINGULAR FOCUS MATTERS
Ophthalmology investing requires specialized insight.
Early-stage ophthalmology investing demands fluency across clinical, regulatory, reimbursement, and adoption dynamics. It also requires familiarity with manufacturing and supply chain considerations to recognize when they represent meaningful development risk, whether in drug or device development.
Clinical Fluency
Understanding disease biology, surgical workflows, and the endpoints that determine whether a product succeeds in practice.
01
Regulatory Landscape
Navigating FDA pathways, trial design, and approval timelines specific to ophthalmic therapeutics and devices.
02
Reimbursement Dynamics
Evaluating coverage, coding, and payment structures that determine real-world commercial viability.
03
Adoption Considerations
Assessing whether clinicians and surgeons will actually integrate a new technology into practice — and when.
04
FOR INVESTORS
Designed for a wide range of investors.
Whether you are an experienced angel investor, a physician curious about early-stage investing, or someone outside of medicine who sees the opportunity in ophthalmology, we designed EyeSci Angels with you in mind.
Membership Tier
Observer
No fees, no obligations
Access to selected company presentations
Curated diligence materials and research
Educational resources on ophthalmic investing
Community access and discussion forums
No obligation to invest — ever
Membership Tier
Investor
Full access - invest alongside principals
Everything in Observer membership
Full diligence materials for all reviewed companies
Deal forums and investment participation
Co-invest directly alongside EyeSci Angels principals
Access to the complete member network
Most members begin as Observers and transition to Investing membership once they grow familiar with our diligence process and identify opportunities of interest.
FOR EARLY-STAGE COMPANIES
Building something meaningful in ophthalmology?
If you are building something meaningful in ophthalmology or a closely related field, we want to hear from you. We engage selectively, with genuine domain expertise and a network of investors who understand the space deeply.
Therapeutics & Biologics
Ocular drug delivery, gene therapy, cell therapy, and small-molecule programs targeting retinal and anterior segment disease.
Devices & Surgical Technologies
Implants, instruments, robotics, and enabling platforms that improve surgical outcomes and expand access to care.
Diagnostics, Imaging & AI
Technologies that improve the detection, monitoring, or management of ophthalmic disease at scale.
BUILD EYESCI WITH US
A small, deliberate community built on rigor and shared discovery.
We are building a small, deliberate community of colleagues who find genuine satisfaction in rigorous analysis, meaningful impact, and the shared discovery that early-stage investing at its best can offer.